In type 2 diabetes mellitus patients, anlogliptin benzoate is a dipeptidyl peptidase-4 (DPP-4) inhibitor that requires frequent dosing due to its short half-life, leading to problems with adherence. To improve therapeutic efficacy and compliance with alogliptin benzoate, this study developed and evaluated an extended-release oral dosage form. Modulating drug release with hydroxypropyl methylcellulose (HPMC) and ethyl cellulose was achieved through direct compression with various hydrophilic and hydrophobic polymers. Analogliptin benzoate is compatible with the selected polymers based on preformulation studies. All of the prepared tablets met pharmacopeial standards for physical properties like hardness, friability, weight variation, and uniformity of drug content. A diffusion-controlled release mechanism was demonstrated by the optimized formulation, following the Higuchi model over 24 hours. The extended-release oral dosage form of alogliptin benzoate developed in this study has the potential to enhance patient compliance by reducing dosing frequency and ensuring consistent therapeutic effects.

The spectrophotometric method developed for quantifying Clobazam in bulk and finished pharmaceutical preparations is highly accurate, sensitive, rapid, precise, and economical. Utilizing UV spectrophotometric absorption at 230 nm, the method demonstrates a low Limit of Detection (LOD) of 0.2158 ?g/ml and a Limit of Quantification (LOQ) of 0.6915 ?g/ml, showcasing its ability to detect and quantify low concentrations of Clobazam. A strong linear relationship was observed between 30-90 ?g/ml with a regression equation of Y = 0.0248x and a correlation coefficient of 0.997, indicating excellent linearity. Accuracy was validated with mean percentage recovery ranging from 99.50% to 100%. Precision studies revealed a Relative Standard Deviation (RSD) of 0.42% for intra-day and 0.56% for inter-day measurements, ensuring consistent results. The method’s robustness was confirmed with RSD values below 2.0% under varied conditions. Application to Clobazam tablets yielded assay results of 99.97% with RSD values below 2.0%, demonstrating suitability for routine analysis. Chromatographic parameters showed a capacity factor greater than 2, theoretical plates numbering 8576, and a tailing factor of 1.27, indicating excellent performance. In degradation studies, Clobazam showed less than 6.0% decomposition under thermal, oxidative, and UV conditions. Acidic degradation resulted in 7.80% decomposition, and alkaline conditions produced a major degradant at 2.987 minutes without interfering with the main drug peak at 3.891 minutes, with a drug decomposition percentage of 2.85%. This method reliably distinguishes between Clobazam and its degradation products, making it suitable for precise and accurate analysis even under stressed conditions

All the newly synthesized compounds were characterized by their physical properties and spectral data. The purity of newly synthesized compounds was confirmed by TLC. Spectral analysis (IR, 1H, 13C NMR and Mass spectrometry) of the compounds adequately supported the structures of the synthesized compounds. The appearance of a band between 1764-1623 cm-1 (C=O) in the IR spectra; a singlet peak at ? value 4.3-5.0 for two protons of CH2 of the pyrazolidinedione ring in the 1H NMR spectra and a peak at ? 41.7-46.9 for carbon of CH2 of the pyrazolidinedione ring supports the formation of pyrazolidinedione substituted thiochromene derivatives (20-35). Molecular ion peaks of the synthesized pyrazolidinedione substituted thiochromene derivatives were obtained on the mass spectra, corresponds with their structures. These spectral data satisfactorily supports the formation of the title compounds. The formation of thiochromene and pyrazolidinedione moieties is supported by the reaction mechanism.